Alnylam Pharmaceuticals (NASDAQ:ALNY) Price Target Raised to $250.00

Alnylam Pharmaceuticals (NASDAQ:ALNY) had its price objective boosted by Royal Bank of Canada from $235.00 to $250.00 in a research note published on Tuesday morning, Benzinga reports. They currently have an outperform rating on the biopharmaceutical company’s stock.

A number of other equities research analysts also recently issued reports on the stock. William Blair restated an outperform rating on shares of Alnylam Pharmaceuticals in a report on Monday, April 8th. Canaccord Genuity Group restated a buy rating and issued a $283.00 target price on shares of Alnylam Pharmaceuticals in a report on Friday, June 21st. HC Wainwright restated a buy rating and issued a $400.00 target price on shares of Alnylam Pharmaceuticals in a report on Monday, June 24th. Wells Fargo & Company boosted their target price on shares of Alnylam Pharmaceuticals from $161.00 to $207.00 and gave the company an equal weight rating in a report on Tuesday. Finally, Evercore ISI boosted their price objective on shares of Alnylam Pharmaceuticals from $210.00 to $260.00 and gave the stock an outperform rating in a research note on Tuesday. Eight investment analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the company’s stock. Based on data from MarketBeat, Alnylam Pharmaceuticals currently has an average rating of Moderate Buy and a consensus target price of $247.09.

Alnylam Pharmaceuticals Price Performance

NASDAQ:ALNY opened at $243.00 on Tuesday. The firm has a 50 day simple moving average of $159.86 and a 200-day simple moving average of $164.73. The firm has a market cap of $30.74 billion, a PE ratio of -90.67 and a beta of 0.30. Alnylam Pharmaceuticals has a 1-year low of $141.98 and a 1-year high of $252.87.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last released its earnings results on Thursday, May 2nd. The biopharmaceutical company reported ($0.52) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.75) by $0.23. The company had revenue of $494.33 million during the quarter, compared to analysts’ expectations of $428.01 million. During the same quarter in the previous year, the firm posted ($1.40) earnings per share. Alnylam Pharmaceuticals’s revenue for the quarter was up 54.8% compared to the same quarter last year. As a group, sell-side analysts expect that Alnylam Pharmaceuticals will post -3.75 earnings per share for the current fiscal year.

Insider Buying and Selling at Alnylam Pharmaceuticals

In other Alnylam Pharmaceuticals news, EVP Kevin Joseph Fitzgerald sold 1,198 shares of the stock in a transaction on Tuesday, June 25th. The shares were sold at an average price of $230.99, for a total transaction of $276,726.02. Following the transaction, the executive vice president now directly owns 14,181 shares in the company, valued at approximately $3,275,669.19. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. In other Alnylam Pharmaceuticals news, CFO Jeffrey V. Poulton sold 1,605 shares of the stock in a transaction on Tuesday, June 25th. The shares were sold at an average price of $231.00, for a total transaction of $370,755.00. Following the transaction, the chief financial officer now directly owns 28,892 shares in the company, valued at approximately $6,674,052. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP Kevin Joseph Fitzgerald sold 1,198 shares of the stock in a transaction on Tuesday, June 25th. The shares were sold at an average price of $230.99, for a total transaction of $276,726.02. Following the transaction, the executive vice president now owns 14,181 shares in the company, valued at $3,275,669.19. The disclosure for this sale can be found here. Insiders have sold 67,357 shares of company stock worth $13,436,711 in the last ninety days. 1.50% of the stock is owned by insiders.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in ALNY. Allspring Global Investments Holdings LLC lifted its position in shares of Alnylam Pharmaceuticals by 572.0% in the 1st quarter. Allspring Global Investments Holdings LLC now owns 168 shares of the biopharmaceutical company’s stock worth $25,000 after buying an additional 143 shares during the last quarter. Altitude Crest Partners Inc. bought a new position in shares of Alnylam Pharmaceuticals in the 1st quarter worth about $30,000. Quent Capital LLC lifted its position in shares of Alnylam Pharmaceuticals by 246.0% in the 4th quarter. Quent Capital LLC now owns 173 shares of the biopharmaceutical company’s stock worth $33,000 after buying an additional 123 shares during the last quarter. Anchor Investment Management LLC bought a new position in shares of Alnylam Pharmaceuticals in the 4th quarter worth about $38,000. Finally, Robeco Institutional Asset Management B.V. lifted its position in shares of Alnylam Pharmaceuticals by 155.7% in the 4th quarter. Robeco Institutional Asset Management B.V. now owns 20,549 shares of the biopharmaceutical company’s stock worth $39,000 after buying an additional 12,513 shares during the last quarter. 92.97% of the stock is currently owned by institutional investors.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.